A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

Estimated effectiveness was 65% against hospitalization, 74% against pediatric intensive care unit admission, and 64% against ...

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving them. Factors such as older maternal age, private insurance, and receipt ...

Getting vaccinated during pregnancy protects your newborn from severe infection during the first critical months of life.

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

Nirsevimab is a long-acting monoclonal antibody designed to provide passive immunity against RSV in infants and young children. The Advisory Committee on Immunization Practices (ACIP) recommends ...

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.It will mean all newborn ...

It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved drug in Europe to provide passive prophylaxis against RSV ...